vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Oportun Financial Corp (OPRT). Click either name above to swap in a different company.
Oportun Financial Corp is the larger business by last-quarter revenue ($247.7M vs $168.4M, roughly 1.5× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -1.3%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -0.5%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Oportun Financial Corp is a US-based fintech firm that provides accessible, responsible financial services including personal loans, credit cards, and savings products to underserved low-to-moderate income consumers, many with limited or no credit history, leveraging proprietary AI underwriting to deliver fair terms while mitigating operational risk.
ESPR vs OPRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $247.7M |
| Net Profit | — | $3.4M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 2.6% |
| Net Margin | — | 1.4% |
| Revenue YoY | 143.7% | -1.3% |
| Net Profit YoY | — | -61.0% |
| EPS (diluted) | $0.32 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $247.7M | ||
| Q3 25 | $87.3M | $238.7M | ||
| Q2 25 | $82.4M | $234.3M | ||
| Q1 25 | $65.0M | $235.9M | ||
| Q4 24 | $69.1M | $250.9M | ||
| Q3 24 | $51.6M | $250.0M | ||
| Q2 24 | $73.8M | $250.4M | ||
| Q1 24 | $137.7M | $250.5M |
| Q4 25 | — | $3.4M | ||
| Q3 25 | $-31.3M | $5.2M | ||
| Q2 25 | $-12.7M | $6.9M | ||
| Q1 25 | $-40.5M | $9.8M | ||
| Q4 24 | — | $8.7M | ||
| Q3 24 | $-29.5M | $-30.0M | ||
| Q2 24 | $-61.9M | $-31.0M | ||
| Q1 24 | $61.0M | $-26.4M |
| Q4 25 | 50.6% | 2.6% | ||
| Q3 25 | -11.4% | 6.0% | ||
| Q2 25 | 8.6% | 4.3% | ||
| Q1 25 | -34.0% | 5.6% | ||
| Q4 24 | -6.4% | 89.6% | ||
| Q3 24 | -31.0% | -15.8% | ||
| Q2 24 | 3.5% | -19.6% | ||
| Q1 24 | 52.5% | -12.2% |
| Q4 25 | — | 1.4% | ||
| Q3 25 | -35.9% | 2.2% | ||
| Q2 25 | -15.4% | 2.9% | ||
| Q1 25 | -62.2% | 4.1% | ||
| Q4 24 | — | 200.1% | ||
| Q3 24 | -57.2% | -12.0% | ||
| Q2 24 | -83.9% | -12.4% | ||
| Q1 24 | 44.3% | -10.6% |
| Q4 25 | $0.32 | $0.07 | ||
| Q3 25 | $-0.16 | $0.11 | ||
| Q2 25 | $-0.06 | $0.14 | ||
| Q1 25 | $-0.21 | $0.21 | ||
| Q4 24 | $-0.14 | $0.26 | ||
| Q3 24 | $-0.15 | $-0.75 | ||
| Q2 24 | $-0.33 | $-0.78 | ||
| Q1 24 | $0.34 | $-0.68 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $105.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $390.1M |
| Total Assets | $465.9M | $3.3B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | $105.5M | ||
| Q3 25 | $92.4M | $104.6M | ||
| Q2 25 | $86.1M | $96.8M | ||
| Q1 25 | $114.6M | $78.5M | ||
| Q4 24 | $144.8M | $60.0M | ||
| Q3 24 | $144.7M | $71.8M | ||
| Q2 24 | $189.3M | $72.9M | ||
| Q1 24 | $226.6M | $69.2M |
| Q4 25 | $-302.0M | $390.1M | ||
| Q3 25 | $-451.4M | $383.9M | ||
| Q2 25 | $-433.5M | $376.0M | ||
| Q1 25 | $-426.2M | $366.1M | ||
| Q4 24 | $-388.7M | $353.8M | ||
| Q3 24 | $-370.2M | $327.6M | ||
| Q2 24 | $-344.2M | $354.1M | ||
| Q1 24 | $-294.3M | $382.0M |
| Q4 25 | $465.9M | $3.3B | ||
| Q3 25 | $364.0M | $3.2B | ||
| Q2 25 | $347.1M | $3.2B | ||
| Q1 25 | $324.0M | $3.2B | ||
| Q4 24 | $343.8M | $3.2B | ||
| Q3 24 | $314.1M | $3.3B | ||
| Q2 24 | $352.3M | $3.3B | ||
| Q1 24 | $373.1M | $3.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $413.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | 121.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $413.4M | ||
| Q3 25 | $-4.3M | $99.0M | ||
| Q2 25 | $-31.4M | $104.5M | ||
| Q1 25 | $-22.6M | $101.0M | ||
| Q4 24 | $-35.0M | $393.5M | ||
| Q3 24 | $-35.3M | $108.5M | ||
| Q2 24 | $-7.2M | $107.7M | ||
| Q1 24 | $53.8M | $85.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $-35.5M | — | ||
| Q2 24 | $-7.3M | — | ||
| Q1 24 | $53.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -68.7% | — | ||
| Q2 24 | -9.9% | — | ||
| Q1 24 | 39.0% | — |
| Q4 25 | 0.0% | — | ||
| Q3 25 | 0.0% | — | ||
| Q2 25 | 0.0% | — | ||
| Q1 25 | 0.0% | — | ||
| Q4 24 | 0.0% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.1% | — | ||
| Q1 24 | 0.1% | — |
| Q4 25 | — | 121.45× | ||
| Q3 25 | — | 19.05× | ||
| Q2 25 | — | 15.20× | ||
| Q1 25 | — | 10.34× | ||
| Q4 24 | — | 45.04× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 0.88× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
OPRT
Segment breakdown not available.
